Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;22(12):2357-2363.
doi: 10.1007/s12094-020-02380-0. Epub 2020 Jun 1.

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

A Arnold  1 , S Daum  2   3 , M von Winterfeld  4 , E Berg  1 , M Hummel  1 , B Rau  5 , U Stein  6   7 , C Treese  8   9   10
Affiliations

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

A Arnold et al. Clin Transl Oncol. 2020 Dec.

Abstract

Introduction: The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S).

Methods: This study analyzed the prevalence, characteristics and prognostic impact of Claudin 18.2 expression in primary tumor, lymph node and distant metastasis in a large Caucasian AGE/S cohort with 414 patients.

Results: Claudin 18.2 was highly expressed in 17.1% of primary tumors, 26.7% of lymph node metastasis and 16.7% of distant metastasis. High Claudin 18.2 expression in lymph node metastasis and primary tumors correlated significantly (p < 0.001). High expression of Claudin 18.2 was neither associated with histomorphogical subtype, or tumor state, nor with overall survival.

Conclusion: In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype.

Keywords: Claudin 18.2; Claudiximab; Esophageal cancer; Gastric cancer; IMAB362.

PubMed Disclaimer

Conflict of interest statement

The author(s) declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Representative Claudin 18.2 IHC staining of TMA cores using the anti-CLDN 18.2 clone 43-14A. Examples of tumor samples with IRS = 0.4.6 and 12 (100 × and 400 × magnitude)
Fig. 2
Fig. 2
Kaplan–Meier plots of overall survival. Claudin 18.2 neg.: gray; pos.: black. Significance calculated by log rank: no significant differences in survival between Claudin 18.2-negative (black) and -positive (gray) patients (p = 0.944)
See this image and copyright information in PMC

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953. - PubMed
    1. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Elsevier Ltd. 2010;376:687–697. - PubMed
    1. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235. - PubMed
    1. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Human cancer biology Claudin-18 splice Variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–7635. - PubMed
    1. Trarbach T, Schuler M, Zvirbule Z, Lordick F, Krilova A, Helbig U, et al. Efficacy and safety study of multiple doses of IMAB362 in patients with advanced gastroesophageal cancer. Ann Oncol. 2014;25:iv218.

MeSH terms